According to the report, the global cancer monoclonal antibody market is likely to grow from USD 103.8 Billion in 2025 to USD 259.6 Billion in 2035 at a highest CAGR of 9.6% during the time period. The cancer monoclonal antibody market is growing as the burden of cancer rises, and preference for targeted therapy, which is mechanism-specific, is accelerating to achieve better treatment outcomes and lower the reliance on non-specific approaches. A wider adoption of biomarker testing is helping to more accurately identify patient subsets who should benefit from antibody-based therapies, and improvements in antibody engineering are fueling next-generation formats such as bispecific antibodies.
Furthermore, the use of monoclonal antibodies is becoming more common in combination regimens with chemotherapy, targeted agents and immune-based agents, broadening their use in the treatment of solid tumors and hematological malignancies. New therapies for unmet tumor indications are expanding the patient population addressed.
The pipeline continues to strengthen, as clinical trials of bispecifics are expanding in number, and into earlier treatment scenarios, as are trials for combinations, and as drug companies invest in antibody platforms for oncology. The market is growing at a faster pace and the therapeutic application of monoclonal antibodies is expanding as the use of precision oncology increases and the innovation of new antibodies expands into new cancer indications.
“Key Driver, Restraint, and Growth Opportunity Shaping the Global Cancer Monoclonal Antibody Market
The shift of monoclonal antibody use from later-line cancer treatment into earlier-line treatment is driving increased demand. The use of monoclonal antibodies extends to earlier lines of therapy, they have the potential to create further demand. Early intervention can expand patient populations eligible for treatment, extend the duration of therapy, and where clinical evidence shows benefits in terms of meaningful survival or recurrence benefits.
Therapeutic alternatives like antibody-drug conjugates, cell therapies, targeted small molecules, and radioligand therapy pose threats to the market. Greater clinical success and regulatory approval of these modalities will help remove some of the treatment and pharmaceutical dollars from traditional monoclonal antibodies. In particular, the growing number of oncology drugs in the pipeline is creating competition for treatment lines with multiple targeted drugs.
The transition from intravenous infusion to subcutaneous administration opens up potential avenues to enhance convenience for treatment, decrease infusion center needs, and facilitate the delivery of cancer care in a decentralized model. This opportunity has been reinforced recently by regulatory activity as the FDA approved Sanofi's Sarclisa Escena by subcutaneous injection on July 2026, for several multiple-myeloma indications.
Regional Analysis of Global Cancer Monoclonal Antibody Market
Key players in the global cancer monoclonal antibody market include prominent companies such as AbbVie Inc., Amgen Inc., AstraZeneca PLC, BeiGene Ltd., BioNTech SE, Bristol Myers Squibb, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Genmab A/S, GSK plc, Innovent Biologics, Inc., Johnson & Johnson, Merck & Co., Inc., Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals, Inc., Shanghai Junshi Biosciences Co., Ltd, Other Key Players.
The global cancer monoclonal antibody market has been segmented as follows:
Global Cancer Monoclonal Antibody Market Analysis, by Antibody Source
Global Cancer Monoclonal Antibody Market Analysis, by Antibody Type
Global Cancer Monoclonal Antibody Market Analysis, by Target Antigen
Global Cancer Monoclonal Antibody Market Analysis, by Therapy Type
Global Cancer Monoclonal Antibody Market Analysis, by Cancer Indication
Global Cancer Monoclonal Antibody Market Analysis, by Expression Technology
Global Cancer Monoclonal Antibody Market Analysis, by Treatment Line
Global Cancer Monoclonal Antibody Market Analysis, by Route of Administration
Global Cancer Monoclonal Antibody Market Analysis, by Molecule Origin
Global Cancer Monoclonal Antibody Market Analysis, by Region
About Us
MarketGenics is a global market research and management consulting company empowering decision makers from startups, Fortune 500 companies, non-profit organizations, universities and government institutions. Our main goal is to assist and partner organizations to make lasting strategic improvements and realize growth targets. Our industry research reports are designed to provide granular quantitative information, combined with key industry insights, aimed at assisting sustainable organizational development.
We serve clients on every aspect of strategy, including product development, application modeling, exploring new markets and tapping into niche growth opportunities.
USA Address:
800 N King Street Suite 304 #4208 Wilmington, DE 19801 United States.
+1(302)303-2617
info@marketgenics.co
India Address:
3rd floor, Indeco Equinox, Baner Road, Baner, Pune, Maharashtra 411045 India.
sales@marketgenics.co
Table of Contents
Note* - This is just tentative list of players. While providing the report, we will cover more number of players based on their revenue and share for each geography
We will customise the research for you, in case the report listed above does not meet your requirements.
Get 10% Free Customisation